The partnership will allow the pharma giant to deliver drugs straight to consumers
Eli Lilly And Co (NYSE:LLY) today announced a new partnership with Amazon.com's (AMZN) pharmacy to deliver drugs ordered via its LillyDirect service, including weight loss medication Zepbound, straight to consumers. The stock is down 0.4% at $751.86 at last check, with today's update also weighing on Walgreens Boots Alliance (WBA), which last month lost its spot on the Dow Jones Industrial Average (DJIA) to AMZN.
The $720 level emerged as a floor for Eli Lilly stock after it hit a March 4, record high of $800.78, which contributed to its impressive 130.8% year-over-year lead. The 40-day moving average has also been acting as a consistent level of support so far this year.
Short-term options traders have been much more bullish than usual. This is per LLY's Schaeffer's put/call open interest ratio (SOIR) of 0.67 that sits higher than 5% of annual readings.